DeltEx drug resistant immunotherapy (DRI) γδ T cells — FDA meeting
2H26
• Guidance from the FDA on potential accelerated regulatory pathways for GBM program in 2H26.Source filing
INAB biotech catalysts & pipeline
IN8BIO INC · Data as of 2026-09-08
Upcoming catalysts
INB-619 — Initial data
H2 2026
Initial in vivo data expected in the second half of 2026Source filing
INB-619 — IND submission
2027
We expect to present preliminary animal model data in 2026, with a goal of submitting an IND in 2027.Source filing
INB-100 — Conference presentation
late 2026
INB-100 program clinical update at a scientific meeting in late 2026.Source filing
INB-200/400 (DeltEx DRI) — Conference presentation
Late 2026
We continue to believe that our DeltEx DRI approach has the potential to address this significant unmet need and expect to provide further clinical updates, including additional mOS data from the total data set, at medical meetings in mid- and late- 2026.Source filing